Management of spasticity in progressive multiple sclerosis: Efficacy of repeated intrathecal triamcinolone acetonide administration

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4564-4569

  Abu Mugheisib, Mazen ^a   Benecke, Reiner ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Intrathecal steroids; Multiple sclerosis; Spasticity; Triamcinolone acetonide

Indexed keywords

METHYLPREDNISOLONE ACETATE; MITOXANTRONE; TRIAMCINOLONE ACETONIDE;

ARTICLE; DISABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SPASTICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, SPINAL; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MUSCLE SPASTICITY; TRIAMCINOLONE ACETONIDE;

EID: 84866377175     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502251     Document Type: Article

References (59)

1. National Multiple Sclerosis Society-About research. Available at http://www.nationalmssociety.org/Research-FactSheet.asp. Accessed Oct 19. 2010.
2. Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Seminars in Neurology 2003; 23(2): 133-146.
3. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-1438.
4. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-782.
5. Henze T, Rieckmann P, Toyka KV. Symptomatic Treatment of Multiple Sclerosis. Eur Neurol 2006; 56: 78-105.
6. Ward AB. A summary of spasticity management - a treatment algorithm. Eur J Neurol (9 Suppl) 2002; 1: 48-52.
7. Mazen Abu-Mugheisib, Reiner Benecke, Uwe K. Zettl, "Repeated Intrathecal Triamcinolone Acetonide Administration in Progressive Multiple Sclerosis: A Review," Multiple Sclerosis International, vol. 2011, Article ID 219049, 8 pages, 2011. doi: 10.1155/2011/219049
8. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP Spasticity: disordered control. Yearbook Medical, Chicago 1980; pp 485-494.
9. Young RR. Spasticity: a review. Neurology 1994; 44: S12-S20
10. Young RR. Treatment of spastic paresis. N Engl J Med 1989; 320: 1553-1555.
11. Young RR. Spastic paresis. In Multiple Sclerosis Diagnosis, Medical, Management, and Rehabilitation. Edited by Burks JS, Johnson KP. New York: Demos Medical Publishing; 2000: 299-306.
12. Barnes MP. Neurological rehabilitation - a working party report of the British Society of Rehabilitation Medicine and the Neurological, Alliance. British Society of Rehabilitation Medicine, London; 1992
13. Shakespeare D, Boggild M, Young CA. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2003, Issue 4.
14. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-542.
15. Wade DT. Measurement in neurological rehabilitation. Curr Opin Neurol Neurosurg. 1992; 5: 682-686.
16. Tardieu G, Shentoub S, Delarue R. Research on a technic for measurement of spasticity. Revue Neurologique 1954; 91: 143-144
17. Ward, AB. Spasticity treatment with botulinum toxins. J Neural Transm 2008; 115: 607-616
18. Wartenburg R. Pendulousness of the legs as a diagnostic test. Neurology 1951; 1: 18-24
19. Johnson GR. Measurement of spasticity. In: Barnes MP, Johnson GR. Upper motor neuron syndrome and spasticity: clinical management and Neurophysiology. Cambridge University Press, Cambridge 2001; pp 79-95
20. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58(2): 169-178.
21. Heun R, Sliwka U, Ruttinger H, et al. Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study. J Neurol 1992; 239: 31-35.
22. Nelson DA, Landau WM. Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports. J Neurol Neurosurg Psychiatry 2001; 70(4): 433-443.
23. Rohrbach E, Kappos L, Städt D. et al. Intrathecal versus oral corticosteroid therapy of spinal symptoms in multiple sclerosis: a double-blind controlled trial. Neurology 1988; 38(Suppl 1): 256.
24. Rohrbach E KL, Städt D, Hennes A, et al. Effects, side-effecs and pharmacokinetics of intrathecal vs. oral corticosteroids in spinal symptoms of multiple sclerosis: results of a double-blind controlled trial. J Neurol 1988; 235 [Suppl]: 40-41.
25. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343: 1514-1519.
26. Hoffmann V, Schimrigk S, Islamova S, et al. Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neurol Sci 2003; 211(1-2): 81-84.
27. Hellwig K, Stein FJ, Przuntek H, Müller T. Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms. BMC Neurol. 2004; 4(1): 18.
28. Hoffmann V, Kuhn W, Schimrigk S, et al. Repeat intrathecal triamcinolone acetonide application is beneficial in progressive MS patients. Eur J Neurol 2006; 13: 72-76.
29. Comi G, Leocani L, Medaglini S, et al. Evoked potentials in diagnosis and monitoring of multiple sclerosis. Electroencephalogr Clin Neurophysiol Suppl 49; 1999: 13-18.
30. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing- remitting MS. Neurology 2001; 57: 1239-1247.
31. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001; 58(1): 91-97.
32. Martino G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders. Lancet Neurol 2004; 3(6): 372-378.
33. Jongen PJ, Floris S, Doesburg WH, Lemmens WA, Hommes OR, Lamers KJ. Composite cerebrospinal fluid score in relapsingremitting and secondary progressive multiple sclerosis. Mult Scler 1998; 4: 108-110.
34. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720-1725.
35. Michetti F, Massaro A, Murazio M. The nervous systemspecific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients. Neuroscience Letters 1979; 11: 171-175.
36. Massaro AR, Michetti F, Laudisio A, Bergonzi P. Myelin basic protein and S-100 antigen in cerebrospinal fluid of patients with multiple sclerosis in the acute phase. Italian J Neurological Sci 1985; 6: 53-56.
37. Lamers KJ, van Engelen BG, Gabreels FJ, Hommes OR, Borm GF, Wevers RA. Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders. Acta Neurol Scand 1995; 92: 247-251.
38. Melcangi RC, Cavarretta I, Magnaghi V, Ciusani E, Salmaggi A. Corticosteroids protect oligodendrocytes from cytokine-induced cell death. Neuroreport 2000; 11(18): 3969-3972.
39. Jimenez-Jimenez FJ, Zurdo JM, Hernanz A, et al. Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 2002; 106: 351-354.
40. Martinez-Yelamos A, Saiz A BJ, Hernandez JJ, Graus F, Arbizu T. Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsingremitting multiple sclerosis. Neuroscience Letters 2004; 363(1): 14-17.
41. Goodkin DE, Kinkel RP, Weinstock-Guttman B, et al. A phase II study of i.v. methylprednisolone in secondary progressive multiple sclerosis. Neurology 1998; 51: 239-245.
42. Martinelli BF, Rovaris M, Capra R, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005: CD002127.
43. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 2005; 19: 369-376.
44. Goffette S, van Pesch V, Vanoverschelde JL, et al. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. J Neurol 2005; 252: 1217-1222.
45. Hellwig K, Schimrigk S, Lukas C, et al. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Clin Neuropharmacol. 2006; 29(5): 286-291.
46. Van Buskirk C, Poffenbarger AL, Capriles LF, et al. Treatment of multiple sclerosis with intrathecal steroids. Neurology 1964; 14: 595-597.
47. Goldstein NP, McKenzie BF, McGuckin WF, et al. Experimental intrathecal administration of methylprednisolone acetate in multiple sclerosis. Trans Am Neurol Assoc 1970; 95: 243-244.
48. Nelson DA, Vates TS, Thomas RB. Complications from intrathecal steroid therapy in patients with multiple sclerosis. Acta Neurol Scand 1973; 49: 176-188.
49. Nelson DA. Arachnoiditis from intrathecally given corticosteroids in the treatment of multiple sclerosis. Arch Neurol 1976; 33: 373.
50. Dougherty JH, Fraser RA. Complications following intraspinal injections of steroids. J Neurosurg 1978; 48(6): 1023-1025.
51. Bernat JL, Sadowsky CH, Vincent FM, et al. Sclerosing pachymeningitis, a complication of intrathecal administration of Depo-Medrol for multiple sclerosis. J Neurol Neurosurg Psychiatry 1976; 39: 1124-1128.
52. Wilkinson HA. Intrathecal Depo-Medrol: a literature review. Clin J Pain 1992; 8: 49-56.
53. Rivera VM. Safety of intrathecal steroids in multiple sclerosis. Arch Neurol 1989; 46: 718-719.
54. Müller T. Role of intraspinal steroid application in patients with multiple sclerosis. Expert Rev Neurother. 2009; 9(9) 1279-1287
55. Braune HJ, Huffmann GA. A prospective double-blind clinical trial, comparing the sharp Quincke needle (22G) with an "atraumatic" needle (22G) in the induction of post-lumbar puncture headache. Acta Neurol Scand 1992; 86(1): 50-54.
56. Carbaat PA, van Crevel H. Lumbar puncture headache: controlled study on the preventive effect of 24 hours' bed rest. Lancet 1981; 2: 1133-1135.
57. Henze T, Rieckmann P, Toyka KV. Multiple Sclerosis Therapy Consensus Group of the German Multiple Sclerosis Society. Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006; 56(2): 78-105.
58. Boines GJ. Remissions in multiple sclerosis following intrathecal methylprednisolone acetate. Del Med J 1961; 33: 231-235.
59. Boines GJ. Predictable remissions in multiple sclerosis. Del Med J 1963; 35: 200-203.